- BCAL Diagnostics (BDX) signs an agreement with US company Precion to further develop its blood-based test to detect breast cancer
- The company says the agreement marks an important milestone as it works towards commercialising its viable test and making it available to women of all ages and backgrounds
- BCAL’s US and Sydney teams will work directly with Precion’s North Carolina laboratories to develop standardised commercial assays
- The agreement reportedly reflects BCAL’s ongoing commitment to bring to market novel diagnostic blood tests based on proprietary technology to advance the detection of cancer
- Shares in BCAL are up 18.3 per cent to trade at 7.1 cents as of 2:14 pm AEST
BCAL Diagnostics (BDX) has signed an agreement with US company Precion for the next stage of development of the company’s blood-based test to detect breast cancer.
The company said the agreement marks an important milestone as it works towards commercialising its viable test and making it available to women.
Breast cancer is the most common cancer that affects women globally, with over two million new cases every year and approximately 685,000 of those result in death. Due to this, there’s an emphasis on the importance of early detection for effective treatment.
Under the agreement, the company’s US and Sydney teams will work directly with Precion’s North Carolina laboratories for the development of standardised commercial assays.
The assays will be based on the proprietary lipid biomarker signature BCAL identified in the blood samples of early and late-stage breast cancer cohorts.
BCAL CEO Dr John Hurrell called the agreement another key step achieved as the company moves closer to benefitting breast cancer patients and women in general.
The execution of this agreement reflects BCAL’s ongoing commitment to bring to market novel diagnostic blood tests based on proprietary technology to advance the detection of cancer.
Its non-invasive blood test is designed to complement current imaging technologies with the aim of becoming an effective monitoring and screening tool for women of all ages. Results to date have shown 91 per cent specificity and an 87 per cent accuracy.
Over the last five years, BCAL has applied its patented technology to extensive research using the novel approach of molecular lipid analysis for the detection of cancer.
Preliminary findings for breast cancer were recently presented in a poster at the ASCO 2022 Convention in Chicago.
Shares in BCAL were up 18.3 per cent to trade at 7.1 cents as of 2:14 pm AEST.